Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1999 2
2000 7
2001 2
2002 1
2003 2
2005 4
2006 3
2007 4
2008 2
2009 1
2010 4
2011 5
2012 3
2014 8
2015 2
2016 1
2017 4
2018 2
2019 3
2020 6
2021 3
2022 6
2023 5
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Gerstein HC, et al. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28. N Engl J Med. 2021. PMID: 34215025 Free article. Clinical Trial.
Rivaroxaban: searching the integral vascular protection.
Barrios V, Almendro-Delia M, Facila L, Garcia-Moll X, Mazón P, Camafort M, Cepeda JM, Mediavilla Garcia JD, Pose Reino A, Suarez Fernandez C. Barrios V, et al. Among authors: garcia moll x. Expert Rev Clin Pharmacol. 2018 Jul;11(7):719-728. doi: 10.1080/17512433.2018.1495559. Epub 2018 Jul 18. Expert Rev Clin Pharmacol. 2018. PMID: 29965791 Review.
Role of rivaroxaban in the prevention of atherosclerotic events.
Sanmartín M, Bellmunt S, Cosín-Sales J, García-Moll X, Riera-Mestre A, Almendro-Delia M, Hernández JL, Lozano F, Mazón P, Suarez Fernández C. Sanmartín M, et al. Among authors: garcia moll x. Expert Rev Clin Pharmacol. 2019 Aug;12(8):771-780. doi: 10.1080/17512433.2019.1637732. Epub 2019 Jul 9. Expert Rev Clin Pharmacol. 2019. PMID: 31269825 Review.
[Ischemic heart disease: 2006 update].
García-Moll X, Bardají A, Alonso J, Bueno H. García-Moll X, et al. Rev Esp Cardiol. 2007 Feb;60 Suppl 1:3-18. doi: 10.1157/13099709. Rev Esp Cardiol. 2007. PMID: 17352852 Free article. Review. Spanish.
Comments on the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension.
SEC Working Group for the 2018 ESC ESH Guidelines on Arterial Hypertension; Expert Reviewers for the 2018 ESC ESH Guidelines on Arterial Hypertension; SEC Guidelines Committee. SEC Working Group for the 2018 ESC ESH Guidelines on Arterial Hypertension, et al. Rev Esp Cardiol (Engl Ed). 2019 Feb;72(2):104-108. doi: 10.1016/j.rec.2018.12.001. Rev Esp Cardiol (Engl Ed). 2019. PMID: 30704721 English, Spanish. No abstract available.
Comments on the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular disease.
Joint Working Group of the SEC and SEEN for the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases, Expert Reviewers for the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases, and the SEC Guidelines Committee; Joint Working Group of the Spanish Society of Cardiology and Spanish Society of Endocrinology and Nutrition on the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases; Spanish Society of Cardiology; Spanish Society of Endocrinology and Nutrition; Expert reviewers for the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases; SEC Guidelines Committee. Joint Working Group of the SEC and SEEN for the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases, Expert Reviewers for the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases, and the SEC Guidelines Committee, et al. Rev Esp Cardiol (Engl Ed). 2020 May;73(5):354-360. doi: 10.1016/j.rec.2019.11.018. Epub 2020 Mar 20. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32205102 English, Spanish. No abstract available.
Comments on the ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology.
Grupo de Trabajo de SEC para Guía ESC2011 de SCASEST; Fernández-Ortiz A, Pan M, Alfonso F, Arós F, Barrabés JA, Bodí V, Cequiera A, García-Moll X, Jiménez-Candil J, López-Palop R, Peña C, Worner F; Comité de Guías de Práctica Clínica de SEC; Alonso Gómez AM, Anguita M, Cequier A, Comín J, Fernández-Ortiz A, Pan M, Worner F, Alonso J, Bardají A, Barón-Esquivias G, Bover R, Angel-Ferrer J, Goicolea J, Gómez-Doblas JJ, Iñiguez A, Mainar V, Marín F, Pedreira M, Roldán I, Sabaté M, Sánchez PL, Sanchis J. Grupo de Trabajo de SEC para Guía ESC2011 de SCASEST, et al. Among authors: garcia moll x. Rev Esp Cardiol (Engl Ed). 2012 Feb;65(2):125-30. doi: 10.1016/j.recesp.2011.12.003. Rev Esp Cardiol (Engl Ed). 2012. PMID: 22265200 Review. English, Spanish. No abstract available.
80 results